JP2005528886A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005528886A5 JP2005528886A5 JP2003560231A JP2003560231A JP2005528886A5 JP 2005528886 A5 JP2005528886 A5 JP 2005528886A5 JP 2003560231 A JP2003560231 A JP 2003560231A JP 2003560231 A JP2003560231 A JP 2003560231A JP 2005528886 A5 JP2005528886 A5 JP 2005528886A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- nucleic acid
- cell
- sample
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 52
- 229920001184 polypeptide Polymers 0.000 claims description 51
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 35
- 210000004027 cell Anatomy 0.000 claims description 27
- 150000007523 nucleic acids Chemical class 0.000 claims description 26
- 108020004707 nucleic acids Proteins 0.000 claims description 23
- 102000039446 nucleic acids Human genes 0.000 claims description 23
- 230000001575 pathological effect Effects 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims 15
- 241001465754 Metazoa Species 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 6
- 230000007170 pathology Effects 0.000 claims 6
- 239000000126 substance Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000013068 control sample Substances 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 241000238631 Hexapoda Species 0.000 claims 2
- 108700019146 Transgenes Proteins 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 229940124606 potential therapeutic agent Drugs 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 210000005253 yeast cell Anatomy 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 102000034285 signal transducing proteins Human genes 0.000 description 2
- 108091006024 signal transducing proteins Proteins 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000008622 extracellular signaling Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34522202P | 2002-01-04 | 2002-01-04 | |
| US34869302P | 2002-01-14 | 2002-01-14 | |
| US34918202P | 2002-01-16 | 2002-01-16 | |
| US34973302P | 2002-01-17 | 2002-01-17 | |
| US35026302P | 2002-01-18 | 2002-01-18 | |
| US35197702P | 2002-01-24 | 2002-01-24 | |
| US38375802P | 2002-05-28 | 2002-05-28 | |
| US38596902P | 2002-06-05 | 2002-06-05 | |
| US38783402P | 2002-06-11 | 2002-06-11 | |
| US39640702P | 2002-07-17 | 2002-07-17 | |
| US41511502P | 2002-09-30 | 2002-09-30 | |
| US10/336,603 US20040072997A1 (en) | 2000-12-20 | 2003-01-03 | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| PCT/US2003/000252 WO2003060149A2 (en) | 2002-01-04 | 2003-01-06 | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005528886A JP2005528886A (ja) | 2005-09-29 |
| JP2005528886A5 true JP2005528886A5 (enExample) | 2006-02-23 |
Family
ID=27583846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003560231A Pending JP2005528886A (ja) | 2002-01-04 | 2003-01-06 | 治療ポリペプチド、それをコードする核酸、および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040072997A1 (enExample) |
| EP (1) | EP1576168A4 (enExample) |
| JP (1) | JP2005528886A (enExample) |
| AU (1) | AU2003209162A1 (enExample) |
| CA (1) | CA2471480A1 (enExample) |
| WO (1) | WO2003060149A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060205031A1 (en) * | 2003-07-07 | 2006-09-14 | 1) Universiteit Utrecht Holding B.V. | Newly identified cholinephosphotransferases and ethanolaminephosphotransferases |
| US20070105149A1 (en) * | 2003-09-05 | 2007-05-10 | Minomic Pty Ltd | Assay for diabetes |
| WO2005058952A2 (en) * | 2003-12-16 | 2005-06-30 | Zymogenetics, Inc. | Ztnf13, a tumor necrosis factor |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US6083693A (en) * | 1996-06-14 | 2000-07-04 | Curagen Corporation | Identification and comparison of protein-protein interactions that occur in populations |
| AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| JP2003517290A (ja) * | 1999-06-18 | 2003-05-27 | インサイト・ゲノミックス・インコーポレイテッド | ヒト転写調節タンパク質 |
| EP1074617A3 (en) * | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
| CA2402563A1 (en) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| EP1261743A2 (en) * | 2000-03-07 | 2002-12-04 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| CN1333277A (zh) * | 2000-07-07 | 2002-01-30 | 上海博德基因开发有限公司 | 一种新的多肽——人细胞分裂调节蛋白41和编码这种多肽的多核苷酸 |
| WO2002086122A2 (en) * | 2001-03-14 | 2002-10-31 | Hybrigenics | Protein-protein interactions in adipocytes |
| US6441163B1 (en) * | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US20040146970A1 (en) * | 2002-02-08 | 2004-07-29 | Henry Yue | Proteins associated with cell growth, differentiation, and death |
-
2003
- 2003-01-03 US US10/336,603 patent/US20040072997A1/en not_active Abandoned
- 2003-01-06 CA CA002471480A patent/CA2471480A1/en not_active Abandoned
- 2003-01-06 JP JP2003560231A patent/JP2005528886A/ja active Pending
- 2003-01-06 WO PCT/US2003/000252 patent/WO2003060149A2/en not_active Ceased
- 2003-01-06 EP EP03707304A patent/EP1576168A4/en not_active Withdrawn
- 2003-01-06 AU AU2003209162A patent/AU2003209162A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005512515A5 (enExample) | ||
| Bradley et al. | A soluble form of Wnt-1 protein with mitogenic activity on mammary epithelial cells | |
| US20040043932A1 (en) | Leptin-related peptides | |
| JP2003505075A5 (enExample) | ||
| JP2003528611A (ja) | β様糖タンパク質ホルモンのポリペプチドおよびヘテロ二量体 | |
| WO1998022499A9 (en) | Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof | |
| WO1998022499A2 (en) | Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof | |
| KR100227240B1 (ko) | 섬모형 신경성인자 수용체 | |
| JP2005528080A5 (enExample) | ||
| JP4654029B2 (ja) | 単一ドメインｔｄｆ関連化合物およびその類似体 | |
| CA2074361A1 (en) | Merosin, nucleic acids encoding, fragments and uses thereof | |
| JP2003530831A (ja) | βネトリンとその使用 | |
| AU2010225460B2 (en) | Targets for growth factor signalling and methods of therapy | |
| JP2005528886A5 (enExample) | ||
| IE83306B1 (en) | The ciliary neurotrophic factor receptor | |
| JP2004533235A5 (enExample) | ||
| JP2002508934A (ja) | Ｔｎｆレセプターに対して相同性を有する、新規な核酸およびポリペプチド | |
| JP2002300891A (ja) | 新規化合物 | |
| JP2005506833A5 (enExample) | ||
| WO2002030974A2 (en) | Proteins and nucleic acids encoding same | |
| JP2005526507A5 (enExample) | ||
| AU2009210387A1 (en) | Therapeutic Polypeptides, Nucleic Acids Encoding Same, and Methods of Use | |
| WO2001064879A2 (en) | G-proteins coupled receptor related polypeptides | |
| US20040213738A1 (en) | CIRL3-Like proteins, nucleic acids, and methods of modulating CIRL3-L-mediated activity | |
| JP2005504514A5 (enExample) |